JP2002521391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002521391A5 JP2002521391A5 JP2000561222A JP2000561222A JP2002521391A5 JP 2002521391 A5 JP2002521391 A5 JP 2002521391A5 JP 2000561222 A JP2000561222 A JP 2000561222A JP 2000561222 A JP2000561222 A JP 2000561222A JP 2002521391 A5 JP2002521391 A5 JP 2002521391A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hepatitis
- polynucleotide
- subject
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 108010073141 Hepatitis C virus glycoprotein E2 Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000012634 fragment Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98113595 | 1998-07-21 | ||
| EP98113595.7 | 1998-07-21 | ||
| PCT/EP1999/005173 WO2000005266A1 (en) | 1998-07-21 | 1999-07-20 | Anti hepatitis c virus antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002521391A JP2002521391A (ja) | 2002-07-16 |
| JP2002521391A5 true JP2002521391A5 (enExample) | 2006-08-03 |
| JP4593783B2 JP4593783B2 (ja) | 2010-12-08 |
Family
ID=8232320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000561222A Expired - Fee Related JP4593783B2 (ja) | 1998-07-21 | 1999-07-20 | 抗c型肝炎ウイルス抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6951646B1 (enExample) |
| EP (1) | EP1097172A1 (enExample) |
| JP (1) | JP4593783B2 (enExample) |
| CN (2) | CN1325517C (enExample) |
| AU (1) | AU5285899A (enExample) |
| CA (1) | CA2339045A1 (enExample) |
| WO (1) | WO2000005266A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| AU2001232267A1 (en) * | 2000-02-14 | 2001-08-20 | Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases | Remedies for hepatitis c |
| IL137522A (en) * | 2000-07-26 | 2007-06-17 | Drk Blutspendediendst Baden Wu | HCV human monoclonal antibody E2 glycoprotein antibody |
| EP1178116A1 (en) * | 2000-08-03 | 2002-02-06 | Hybrigenics S.A. | Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof |
| GB0021859D0 (en) * | 2000-09-06 | 2000-10-18 | Imp College Innovations Ltd | Methods |
| GB0114629D0 (en) * | 2001-06-15 | 2001-08-08 | Pfizer Ltd | Method |
| ITRM20020049A1 (it) | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| RU2353399C2 (ru) * | 2003-01-17 | 2009-04-27 | Этлон Медикал, Инк. | Способ удаления вирусов из крови посредством лектин-аффинного гемодиализа |
| EP2336176B1 (en) | 2003-04-01 | 2015-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against hepatitis c virus e1e2 complex, and their epitopes |
| GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| EP1765869B1 (en) * | 2004-07-08 | 2015-05-20 | JV Bio S.r.l | Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication |
| DE602006014720D1 (de) * | 2005-10-07 | 2010-07-15 | Proyecto Biomedicina Cima Sl | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| CN103172743B (zh) | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| JP5642972B2 (ja) | 2007-02-21 | 2014-12-17 | ユニバーシティー オブ マサチューセッツUniversity of Massachusetts | C型肝炎ウイルス(hcv)に対するヒト抗体およびその使用 |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| US20110033389A1 (en) * | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| CN102596996B (zh) * | 2009-10-30 | 2014-06-18 | 东丽株式会社 | 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途 |
| BR112012029881A2 (pt) | 2010-05-25 | 2019-09-24 | Inserm (Institut National De La Santé De La Recherche Médicale) | combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN103308697B (zh) * | 2013-06-09 | 2014-11-26 | 卫生部北京医院 | 检测抗丙型肝炎病毒编码的非结构蛋白ns3和ns5的天然双特异性抗体的试剂盒 |
| CN103472233A (zh) * | 2013-06-21 | 2013-12-25 | 温州大学 | 丙型肝炎检测试剂盒及其应用 |
| PT3031826T (pt) | 2013-08-09 | 2019-01-18 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| CN104974246A (zh) * | 2014-04-01 | 2015-10-14 | 中国科学院上海巴斯德研究所 | 一种中和丙型肝炎病毒的全人单克隆抗体及其用途 |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| CN105254756B (zh) * | 2015-11-27 | 2018-09-07 | 武汉大学 | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 |
| CN107286238B (zh) * | 2017-08-07 | 2019-11-26 | 广州泰诺迪生物科技有限公司 | 抗hcv广谱中和抗体的制备、检测以及应用 |
| MA52945A (fr) | 2018-06-22 | 2021-04-28 | Genmab As | Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents |
| AU2019310803B2 (en) | 2018-07-25 | 2022-11-03 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-TIGIT antibody and uses thereof |
| US12304946B2 (en) * | 2018-12-19 | 2025-05-20 | Humabs Biomed Sa | Antibodies that neutralize hepatitis B virus and uses thereof |
| KR20210126559A (ko) | 2018-12-20 | 2021-10-20 | 비르 바이오테크놀로지, 인코포레이티드 | 병용 hbv 요법 |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| US10570210B1 (en) | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
| AU2021228061A1 (en) | 2020-02-27 | 2022-10-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding IL4R and uses thereof |
| US20230272086A1 (en) | 2020-05-12 | 2023-08-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
| EP4259658A4 (en) * | 2020-12-10 | 2024-12-04 | Wuxi Biologics Ireland Limited | An antibody against p-cadherin and uses thereof |
| EP4438055A1 (en) | 2021-11-25 | 2024-10-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-siglec-15 antibody and use thereof |
| EP4495138A1 (en) | 2022-03-18 | 2025-01-22 | Beijing Mabworks Biotech Co., Ltd | B7-h3-binding antibody and use thereof |
| CN118684767B (zh) * | 2024-06-27 | 2025-02-18 | 山东省大健康精准医疗产业技术研究院 | 一种丙肝核心抗原单链抗体及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE520499C (de) | 1929-09-14 | 1931-03-11 | Heinrich Elsner | Vorrichtung zum Biegen von Pappe, Fiber u. dgl. |
| CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| SG71728A1 (en) | 1994-07-29 | 2000-04-18 | Innogenetics Nv | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| US6747136B2 (en) * | 1996-04-19 | 2004-06-08 | Karolinska Innovations Ab | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen |
| EP1127170A4 (en) | 1998-11-05 | 2005-04-27 | Univ Leland Stanford Junior | HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN |
| US6682909B2 (en) | 2000-09-13 | 2004-01-27 | Hawaii Biotech, Inc. | Immunogenic composition of hepatitis C and methods of use thereof |
-
1999
- 1999-07-20 US US09/744,176 patent/US6951646B1/en not_active Expired - Fee Related
- 1999-07-20 WO PCT/EP1999/005173 patent/WO2000005266A1/en not_active Ceased
- 1999-07-20 CA CA002339045A patent/CA2339045A1/en not_active Abandoned
- 1999-07-20 EP EP99938301A patent/EP1097172A1/en not_active Withdrawn
- 1999-07-20 AU AU52858/99A patent/AU5285899A/en not_active Abandoned
- 1999-07-20 JP JP2000561222A patent/JP4593783B2/ja not_active Expired - Fee Related
- 1999-07-20 CN CNB99808641XA patent/CN1325517C/zh not_active Expired - Fee Related
- 1999-07-20 CN CNA2007101063440A patent/CN101088561A/zh active Pending
-
2004
- 2004-10-25 US US10/972,296 patent/US7507408B2/en not_active Expired - Fee Related
-
2008
- 2008-09-09 US US12/207,460 patent/US20090104188A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002521391A5 (enExample) | ||
| CA2406240C (en) | Hcv anti-core monoclonal antibodies | |
| JP2020516300A5 (enExample) | ||
| JP2022169504A5 (enExample) | ||
| HRP20140316T1 (hr) | Humana antitijela protiv virusa hepatitisa c (hcv) i njihova uporaba | |
| CN113549148A (zh) | Hcv核心脂质结合结构域单克隆抗体 | |
| JP2004512824A5 (enExample) | ||
| EP2082032A1 (en) | Hybridomas producing antibodies against non functional p2x7 receptor | |
| JP2008533986A5 (enExample) | ||
| CN115515984A (zh) | 一种抗cd19抗体的抗体及其制备和应用 | |
| JP2008515388A5 (enExample) | ||
| KR102339334B1 (ko) | 인간 메타뉴모바이러스(hMPV)의 항원 M의 특이적 단클론 항체 및 진단 방법에 있어서의 그 용도 | |
| JPH09504377A (ja) | Hcvレセプター結合を検出するためのアッセイ | |
| CN118085082A (zh) | 抗猫TNF-α单克隆抗体及其应用 | |
| KR20250122528A (ko) | 메타뉴모바이러스 융합(f) 단백질에 대한 항체 및 그 용도 | |
| KR102601835B1 (ko) | 말 인플루엔자 바이러스 h3n8형에 특이적인 단일클론항체 및 이를 이용한 말인플루엔자 바이러스 검출용 조성물 | |
| CN117683123A (zh) | 抗狂犬病毒人源化抗体和抗体组合及其用途 | |
| JPH08510635A (ja) | B型肝炎エスケープミュータント特異的結合分子 | |
| TWI741216B (zh) | 專一性抑制或減緩ptx3與ptx3受體結合之單株抗體或其抗原結合片段及其用途 | |
| KR102007161B1 (ko) | 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체 | |
| CN107286237B (zh) | 一种抗丙型肝炎病毒抗体的获取以及应用 | |
| EP3974446A1 (en) | Anti-hepatitis b virus antibodies and use thereof | |
| CN118930642B (zh) | 一种针对乙型脑炎病毒和寨卡病毒的人源单克隆抗体及其应用 | |
| KR102798975B1 (ko) | 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 항체 및 이의 용도 | |
| KR102798983B1 (ko) | 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 항체 및 이의 용도 |